Shanghai, China
OnQuality Pharmaceuticals Ltd. has built a substantial pipeline of products to address unmet clinical needs in the area of oncology supportive care. Currently, the company has one asset in Phase II, three in the pre-IND stage, and two others in the early development stage. These developments showcase the company's commitment to advancing cancer care.
The latest milestone in OnQuality's journey is a $20.00M Series A investment at 31 March 2021. The investment was led by a consortium of prominent investors including Matrix Partners China, Sinovation Ventures, BioTrack Capital, Shiyu Capital, Frees Fund, and CASH Capital. This not only underscores the potential and promise of OnQuality Pharmaceuticals but also highlights the confidence of these high-profile investors in the company's mission and approach.
